We are preparing the requested document. Please wait, this may take a while...!
|Application / Reactivity||Human|
|Blocking Antibody (Inhibition)||2 Antibodies|
|Enzyme Immunoassay (EIA)||7 Antibodies|
|Flow Cytometry (FACS)||4 Antibodies|
|Functional Studies (Func)||2 Antibodies|
|Immunochromatography (IC)||6 Antibodies|
|Immunocytochemistry (ICC)||7 Antibodies|
|Immunofluorescence (Paraffin-embedded Sections) (IF (p))||2 Antibodies|
|Immunohistochemistry (IHC)||13 Antibodies|
|Immunohistochemistry (Frozen Sections) (IHC (fro))||2 Antibodies|
|Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))||8 Antibodies|
|Neutralization (Neut)||9 Antibodies|
|Western Blotting (WB)||85 Antibodies|
|Antigen||Thrombopoietin (THPO) Antibodies|
|Conjugate||This Thrombopoietin antibody is un-conjugated Alternatives|
Enzyme Immunoassay (EIA), Functional Studies (Func), Western Blotting (WB)
|1 reference available|
|Supplier||Log in to see|
Product Details anti-Thrombopoietin AntibodyTarget Details Thrombopoietin Application Details Handling References for anti-Thrombopoietin Antibody (ABIN116255) Images
|Specificity||This antibody reacts with Thrombopoietin.|
|Immunogen||Highly purified recombinant human TPO.|
Target Details ThrombopoietinProduct Details anti-Thrombopoietin Antibody Application Details Handling References for anti-Thrombopoietin Antibody (ABIN116255) Images back to top
|Alternative Name||Thrombopoietin (THPO Antibody Abstract)|
|Background||Synonyms: C-mpl ligand, MGDF, Megakaryocyte colony-stimulating factor, Megakaryocyte growth and development factor, Myeloproliferative leukemia virus oncogene ligand, THPO|
|Research Area||Cancer, Cell Cycle, Hormones|
Application DetailsProduct Details anti-Thrombopoietin Antibody Target Details Thrombopoietin Handling References for anti-Thrombopoietin Antibody (ABIN116255) Images back to top
Neutralization: To yield one-half maximal inhibition [ND50] of the biological activity ofhTPO (5.00 ng/mL), a concentration of 4.2-6.3 μg/mL of this antibody is required. ELISA: (Indirect): To detect hTPO by indirect ELISA (using 100 μL/well antibody solution) aconcentration of 0.5-2.0 μg/mL of this antibody is required. This antigen affinity purifiedantibody, in conjunction with compatible secondary reagents, allows the detection of atleast 0.2-0.4 ng/well of recombinant hTPO. (Sandwich): To detect hTPO by sandwich ELISA (using 100 μL/well antibody solution) aconcentration of 0.5-2.0 μg/mL of this antibody is required. This antigen affinity purifiedantibody, in conjunction with Biotinylated Anti-Human TPO (PP1074B) as a detectionantibody, allows the detection of at least 0.2-0.4 ng/well of recombinant hTPO. Western Blot: To detect hTPO by Western Blot analysis this antibody can be used at aconcentration of 0.1-0.2 μg/mL. Used in conjunction with compatible secondary reagentsthe detection limit for recombinant hTPO is 1.5-3.0 ng/lane, under either reducing ornon-reducing conditions.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
|Restrictions||For Research Use only|
HandlingProduct Details anti-Thrombopoietin Antibody Target Details Thrombopoietin Application Details References for anti-Thrombopoietin Antibody (ABIN116255) Images back to top
|Reconstitution||Restore in sterile water to a concentration of 0.1-1.0 mg/mL.|
|Buffer||PBS, pH 7.2 without preservatives.|
|Handling Advice||Avoid repeated freezing and thawing.|
|Storage||4 °C/-20 °C|
|Storage Comment||Store the antibody prior to reconstitution at -20 °C. Following reconstitution the antibody can be stored at 2-8 °C for one month or at -20 °C for longer.|
References for anti-Thrombopoietin Antibody (ABIN116255)Product Details anti-Thrombopoietin Antibody Target Details Thrombopoietin Application Details Handling Images back to top
Xie, Chan, Johnson et al.: "Thrombopoietin promotes mixed lineage and megakaryocytic colony-forming cell growth but inhibits primitive and definitive erythropoiesis in cells isolated from early murine yolk sacs." in: Blood, Vol. 101, Issue 4, pp. 1329-35, 2003 (PubMed).